Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 11,576 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Anemia, Fatigue, Fever, Lymphadenopathy, Lymphocytosis, Night Sweats, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma, Splenomegaly, Thrombocytopenia, Weight Loss
Interventions: Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study, Ritonavir, Quality-of-Life, Questionnaire; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Duarte, California

Conditions: Uveitis, Posterior, Uveitis, Intermediate
Interventions: V404; Drug
Lead sponsor: Forsight Vision4; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Golden, Colorado • Atlanta, Georgia • Omaha, Nebraska + 2 more

Conditions: Cystic Fibrosis (CF), Depressive and Anxiety Disorders, Psychological Flexibility
Interventions: ACT with CF Self-Help Toolkit, Waitlist; Behavioral · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Lymphoma
Interventions: denileukin diftitox; Biological
Lead sponsor: Pharmatech Oncology; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 6
States / cities: Pomona, California • Rancho Mirage, California • Saint Charles, Missouri + 3 more

Conditions: Cerebral Palsy
Interventions: Let's Move Motor Intervention; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Months to 8 Months
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Otitis Media, Otitis Media Chronic, Otitis Media Effusion
Interventions: SWIR device; Device
Lead sponsor: Stanford University; Other
Eligibility: 1 Year to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 116
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more

Conditions: Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure
Interventions: Not listed
Lead sponsor: Fundacion Clinica Valle del Lili; Other
Eligibility: 18 Years and older
Enrollment: 6,732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Manhasset, New York • Dallas, Texas

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, sargramostim, busulfan, fludarabine phosphate, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Migraine
Interventions: Milnacipran, Placebo; Drug
Lead sponsor: Timothy Smith; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: St Louis, Missouri • Greensboro, North Carolina

Conditions: Thrombosis
Interventions: Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 28 Days to 17 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more

Conditions: Osteoarthritis of the Knee
Interventions: NKTR-181, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 34
States / cities: Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more

Conditions: Chronic Back Pain, Opioid Use
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Oral Complications, Sarcoma
Interventions: Traumeel S, Placebo; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 25 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 33 more

Conditions: Stroke, Chronic Phase of Disease
Interventions: Strategy Training Only, Strategy Training embedded with Acceptance and Commitment Therapy Principles; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Heart Failure
Interventions: carvedilol; Drug
Lead sponsor: Cardiovascular Clinical Sciences Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 54
States / cities: Mobile, Alabama • Sierra Vista, Arizona • Anaheim, California + 49 more

Conditions: Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea
Interventions: Oral Glycopyrrolate Liquid; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Lakewood, Colorado • Atlanta, Georgia • Bayside, New York + 4 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
Interventions: Cord Blood Transplant; Procedure
Lead sponsor: Colorado Blood Cancer Institute; Other
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: CKD
Interventions: CKD Report Card; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Disease
Interventions: Educational print materials and coaching call; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Interventions: Low-Dose Naltrexone, 1.5mg, Low-Dose Naltrexone, 3.0mg, Low-Dose Naltrexone, 4.5mg, Low-Dose Naltrexone, 6.0mg; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: St. John's wort; Dietary Supplement
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumonia
Interventions: Interventional 40-60, Interventional 60 and above; Other
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 40 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Long COVID
Interventions: Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: Douglas D. Fraser; Other
Eligibility: 18 Years to 65 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia

Safety and Preliminary Efficacy Study of V404 PDS in Uveitis

ACT With CF Self-Help Toolkit

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Motor Training for Infants With Cerebral Palsy

SWIR Otoscopy Study

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

American Registry of Ambulatory or Acutely Decompensated Heart Failure

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

Adaptations of the Brain in Chronic Pain With Opioid Exposure I

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Rehabilitation Strategies for Social Participation in Chronic Stroke Survivors

Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation

CKD Report Card Pilot Trial

Brief Intervention to Create Smoke-Free Homes Policies in Low-Income Households: North Carolina Effectiveness Trial

Low-Dose Naltrexone For ME/CFS: Dose-Finding

St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer

Effect of Exercise and Education After Pneumonia

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study